Novel Promoter Strategy Inovandudza Kuchengetedzeka uye Kushanda kweCAR-T Therapy muAcute B Cell Leukemia.
Beijing, China - Chikunguru 23, 2024- Mukukura kunokatyamadza, Lu Daopei Hospital, yakabatana neHebei Senlang Biotechnology, yakaburitsa mhedzisiro inovimbisa kubva muongororo yavo yazvino pamusoro pechimeric antigen receptor T (CAR-T) cell therapy. Ichi chidzidzo, chinotarisa kushanda uye kuchengetedzeka kwemasero eCAR-T akagadzirwa nevanokurudzira vakasiyana, inoratidza kufambira mberi kwakakosha mukurapa kwekudzokazve kana refractory acute B cell leukemia (B-ALL).
Chidzidzo ichi, chakanzi "Promoter Use Regulating the Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo," inoongorora kuti kusarudzwa kwekusimudzira kunogona kukanganisa sei kushanda kwemasero eCAR-T. Vatsvagiri Jin-Yuan Ho, Lin Wang, Ying Liu, Min Ba, Junfang Yang, Xian Zhang, Dandan Chen, Peihua Lu, naJianqiang Li vanobva kuHebei Senlang Biotechnology uye Lu Daopei Hospital vakatungamira tsvagiridzo iyi.
Zvavakawana zvinoratidza kuti kushandisa MND (myeloproliferative sarcoma virus MPSV enhancer, negative control region NCR deletion, d1587rev primer binding site replacement) inokurudzira mumasero eCAR-T inotungamira kudzikira kwepamusoro density yemamorekuru eCAR, ayo anozoderedza kugadzirwa kwecytokine. Izvi zvakakosha nekuti zvinobatsira kudzikisira mhedzisiro yakakomba inowanzobatanidzwa neCAR-T therapy, yakadai secytokine release syndrome (CRS) uye CAR-T cell-related encephalopathy syndrome (CRES).
Muedzo wekiriniki, wakanyoreswa pasi peClinicalTrials.gov identifier NCT03840317, waisanganisira varwere gumi nevana vakakamurwa kuita mapoka maviri: mumwe achiwana masero eCAR-T anofambiswa neMND uye mumwe achigamuchira EF1A anosimudzira-anotyairwa masero eCAR-T. Zvinoshamisa kuti varwere vese vakarapwa neMND-inotyairwa CAR-T masero vakawana kuregererwa kwakakwana, uye vazhinji vavo vachiratidza kushoma kwakasara kwechirwere-negative mamiriro mushure memwedzi wekutanga. Chidzidzo chacho chakarondedzerawo chiitiko chakaderera cheCRS yakaoma uye CRES kune varwere vanobatwa neMND-inotungamirirwa neCAR-T masero achienzaniswa nevaya vanobatwa neEF1A-inotungamirirwa nemasero.
Dr. Peihua Lu vekuLu Daopei Hospital vakaratidza tarisiro pamusoro pekugona kweiyi nzira itsva, vachiti, "Kubatana kwedu neHebei Senlang Biotechnology kwapa ruzivo rwakakosha mukugadzirisa CAR-T cell therapy. Nekugadzirisa mutsigiri, tinogona kusimudzira chimiro chekuchengetedza. yekurapa uku ichichengetedza kushanda kwayo.
Chidzidzo ichi chakatsigirwa nerubatsiro kubva ku Natural Science Foundation yeHebei Province uye Dhipatimendi reSainzi neTekinoroji reHebei Province. Inotaridza kukosha kwekusarudzwa kwevanosimudzira mukuvandudzwa kweCAR-T cell therapies uye inovhura nzira nyowani dzekuchengetedza uye zvakanyanya kurapa cancer.